Overview

A Study to Evaluate the Efficacy of Venetoclax in Relapsed/Refractory Participants With Chronic Lymphocytic Leukemia (CLL) Including Those With 17p Deletion or TP53 Mutation or Those Who Have Received a Prior B-cell Receptor Inhibitor

Status:
Active, not recruiting

Trial end date:
2022-09-12

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the efficacy of venetoclax monotherapy in participants with relapsed/refractory CLL including those with the 17p deletion or TP53 mutation OR those who have received prior treatment with a B-cell receptor inhibitor.

Phase:

Phase 3

Details

Lead Sponsor:

AbbVie

Treatments:

Receptors, Antigen, B-Cell
Venetoclax